SurvodutideWeight LossSafety Rating 7/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors
Overview
About Survodutide
Mechanism of action
Dual glucagon receptor (GCGR) and GLP-1 receptor agonist; glucagon component increases energy expenditure and hepatic fat oxidation; GLP-1 component suppresses appetite; synergistic weight loss.
Safety profile
Nausea, vomiting, diarrhea, decreased appetite (class effects); potential hepatic enzyme changes; still in trials. · Phase III for MASH/obesity; GI side effects; promising liver/metabolic effects; well-tolerated in trials
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Survodutide below your target.
Related pages